Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression

[1]  J. Manson,et al.  Marine n-3 fatty acids and prevention of cardiovascular disease and cancer , 2019, Yearbook of Paediatric Endocrinology.

[2]  M. Loda,et al.  The Metabolic Landscape of Prostate Cancer. , 2019, European urology oncology.

[3]  P. Troncoso,et al.  Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo , 2019, Molecular Imaging and Biology.

[4]  J. Manson,et al.  Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease , 2019, The New England journal of medicine.

[5]  K. Shah,et al.  1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis , 2018, Journal of Immunotherapy for Cancer.

[6]  Eric A. Smith,et al.  Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer , 2018, Nature Metabolism.

[7]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[8]  D. Qian,et al.  Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy , 2018, Nature Communications.

[9]  C. Matthews,et al.  Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study. , 2018, International journal of epidemiology.

[10]  K. D. Sørensen,et al.  Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[11]  D. Eberli,et al.  Combined N‐terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells , 2018, The Prostate.

[12]  Yunchao Wang,et al.  Isobavachalcone Induces ROS-Mediated Apoptosis via Targeting Thioredoxin Reductase 1 in Human Prostate Cancer PC-3 Cells , 2018, Oxidative medicine and cellular longevity.

[13]  T. Todenhöfer,et al.  Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. , 2018, Urologic oncology.

[14]  Lai Wang,et al.  The role of ASCT2 in cancer: A review , 2018, European journal of pharmacology.

[15]  M. Loda,et al.  Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. , 2018, Cold Spring Harbor perspectives in medicine.

[16]  D. Hasan,et al.  PKM2 and HIF-1α regulation in prostate cancer cell lines , 2018, PloS one.

[17]  Arkaitz Carracedo,et al.  Rewiring urea cycle metabolism in cancer to support anabolism , 2018, Nature Reviews Cancer.

[18]  Fabrizio Fontana,et al.  Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells , 2018, Cell Death & Disease.

[19]  Dominik Awad,et al.  Delineation of the androgen‐regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches , 2018, Current opinion in pharmacology.

[20]  S. Shariat,et al.  Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[21]  J. Debnath,et al.  Macropinocytosis Fuels Prostate Cancer. , 2018, Cancer discovery.

[22]  Y. Mohammadi,et al.  The association between Selenium and Prostate Cancer: a Systematic Review and Meta-Analysis , 2018, Asian Pacific journal of cancer prevention : APJCP.

[23]  U. Dadwal,et al.  Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment , 2018, Front. Endocrinol..

[24]  J. Mayo,et al.  The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? , 2018, International journal of cancer.

[25]  E. Kikuchi,et al.  PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer , 2018, Oncotarget.

[26]  Shibo Wang,et al.  Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer. , 2018, International journal of biological macromolecules.

[27]  R. Bamezai,et al.  Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition , 2018, Scientific Reports.

[28]  Dorrelyn Patacsil,et al.  TNFAIP8 promotes prostate cancer cell survival by inducing autophagy , 2018, Oncotarget.

[29]  Gonghui Li,et al.  Drug Resistance of Enzalutamide in CRPC. , 2018, Current drug targets.

[30]  N. Hay,et al.  Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation , 2018, eLife.

[31]  N. Taylor,et al.  GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress , 2018, Redox biology.

[32]  M. Tschöp,et al.  Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor. , 2018, Cancer cell.

[33]  Darryl J. Pappin,et al.  Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells , 2018, Cell reports.

[34]  L. Fazli,et al.  Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model , 2018, Investigational New Drugs.

[35]  K. Rajapakshe,et al.  GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. , 2018, Endocrine-related cancer.

[36]  James B. Mitchell,et al.  Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect , 2018, Clinical Cancer Research.

[37]  G. Raj,et al.  Peri‐prostatic adipose tissue: the metabolic microenvironment of prostate cancer , 2018, BJU international.

[38]  Yu Zhao,et al.  Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3. , 2018, Cancer letters.

[39]  C. Evans,et al.  Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study. , 2018 .

[40]  W. Hung,et al.  Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling , 2018, Molecular Cancer.

[41]  X. Gou,et al.  Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells , 2018, International Urology and Nephrology.

[42]  J. Serpa,et al.  Metabolic cooperation between cancer and non-cancerous stromal cells is pivotal in cancer progression , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[43]  Geoff S. Higgins,et al.  Oxidative Phosphorylation as an Emerging Target in Cancer Therapy , 2018, Clinical Cancer Research.

[44]  K. Keshari,et al.  Targeted AKT Inhibition in Prostate Cancer Cells and Spheroids Reduces Aerobic Glycolysis and Generation of Hyperpolarized [1-13C] Lactate , 2018, Molecular Cancer Research.

[45]  J. Erdman,et al.  Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis , 2018, Nutrients.

[46]  N. Kim,et al.  The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy , 2017, Biomolecules & therapeutics.

[47]  Rahul Aggarwal,et al.  Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. , 2017, European urology.

[48]  S. Safe,et al.  Diindolylmethane and its halogenated derivatives induce protective autophagy in human prostate cancer cells via induction of the oncogenic protein AEG-1 and activation of AMP-activated protein kinase (AMPK). , 2017, Cellular signalling.

[49]  P. Bhattacharya,et al.  Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer , 2017, Scientific Reports.

[50]  David M. Evans,et al.  Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis , 2017, bioRxiv.

[51]  P. Stacpoole.  Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer , 2017, Journal of the National Cancer Institute.

[52]  A. Kimmelman,et al.  Metabolic Interactions in the Tumor Microenvironment. , 2017, Trends in cell biology.

[53]  M. Jordá,et al.  Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer , 2017, Nature Communications.

[54]  H. He,et al.  Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer , 2017, Oncogene.

[55]  Jamey D. Young,et al.  Lactate Metabolism in Human Lung Tumors , 2017, Cell.

[56]  Zanna Beharry,et al.  Myristoylation of Src kinase mediates Src-induced and high-fat diet–accelerated prostate tumor progression in mice , 2017, The Journal of Biological Chemistry.

[57]  A. D’Alessandro,et al.  Measurement of metabolic fluxes using stable isotope tracers in whole animals and human patients , 2017, Current opinion in clinical nutrition and metabolic care.

[58]  M. Stampfer,et al.  Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer , 2017, International journal of cancer.

[59]  E. Riboli,et al.  Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study , 2017, BMC Medicine.

[60]  Eric Eidelman,et al.  The Metabolic Phenotype of Prostate Cancer , 2017, Front. Oncol..

[61]  K. Wiman,et al.  Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death , 2017, Cell Death & Disease.

[62]  K. Rajapakshe,et al.  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer , 2017, Molecular Cancer Research.

[63]  A. Wolk,et al.  Dairy intake in relation to prostate cancer survival , 2017, International journal of cancer.

[64]  J. Erdman,et al.  Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis , 2017, Prostate Cancer and Prostatic Diseases.

[65]  P. Sooriakumaran,et al.  Metformin and Prostate Cancer: a New Role for an Old Drug , 2017, Current Urology Reports.

[66]  M. Lucia,et al.  Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade , 2017, Oncotarget.

[67]  John Kurhanewicz,et al.  Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion. , 2017, Cancer research.

[68]  D. Schuster,et al.  Imaging of Prostate Cancer Using Fluciclovine. , 2017, PET clinics.

[69]  A. Joshua,et al.  AR Signaling and the PI3K Pathway in Prostate Cancer , 2017, Cancers.

[70]  X. Gou,et al.  Autophagy activated by the c-Jun N-terminal kinase-mediated pathway protects human prostate cancer PC3 cells from celecoxib-induced apoptosis , 2017, Experimental and therapeutic medicine.

[71]  U. Haberkorn,et al.  Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging , 2017, The Journal of Nuclear Medicine.

[72]  D. Frigo,et al.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer , 2017, Nature Reviews Urology.

[73]  A. Paiardini,et al.  Glucose Metabolism in the Progression of Prostate Cancer , 2017, Front. Physiol..

[74]  M. Kattan,et al.  An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  Zhiquan Hu,et al.  Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation , 2017, Drug design, development and therapy.

[76]  Q. Hu,et al.  Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis , 2017, Oncology reports.

[77]  N. Barlev,et al.  One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy , 2017, Oncotarget.

[78]  R. Pearson,et al.  Therapeutic Approaches Targeting MYC-Driven Prostate Cancer , 2017, Genes.

[79]  Robert Powers,et al.  The future of NMR-based metabolomics. , 2017, Current opinion in biotechnology.

[80]  Zhigang Cui,et al.  Serum selenium levels and prostate cancer risk , 2017, Medicine.

[81]  J. Nesland,et al.  Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers , 2017, Oncotarget.

[82]  R. Franklin,et al.  A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. , 2016, Archives of biochemistry and biophysics.

[83]  C. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[84]  RS Jones,et al.  Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease , 2016, Clinical pharmacology and therapeutics.

[85]  D. Albanes,et al.  Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial , 2016, British Journal of Cancer.

[86]  A. Kibel,et al.  Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression , 2016, Cancer Prevention Research.

[87]  R. Hohl,et al.  Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis , 2016, Cancer biology & therapy.

[88]  W. Cui,et al.  Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination , 2016, Development.

[89]  K. Pienta,et al.  DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis1 , 2016, Neoplasia.

[90]  Y. Miyagi,et al.  Lipid Droplets: A Key Cellular Organelle Associated with Cancer Cell Survival under Normoxia and Hypoxia , 2016, International journal of molecular sciences.

[91]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[92]  Lin Guo,et al.  Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L , 2016, Tumor Biology.

[93]  K. D. Sørensen,et al.  The Potential of MicroRNAs as Prostate Cancer Biomarkers. , 2016, European urology.

[94]  M. Ruiz-Echevarría,et al.  One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling , 2016, International journal of molecular sciences.

[95]  M. Soengas,et al.  Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5 , 2016, Autophagy.

[96]  E. Metter,et al.  Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies , 2016, Journal of the National Cancer Institute.

[97]  M. Zhang,et al.  Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases , 2016, Andrology.

[98]  R. Breau,et al.  Fish-Derived Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review , 2016, Integrative cancer therapies.

[99]  Jing Li,et al.  miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer , 2016, Oncotarget.

[100]  G. Cao,et al.  miR‐132 mediates a metabolic shift in prostate cancer cells by targeting Glut1 , 2016, FEBS open bio.

[101]  Kyoung-Jae Won,et al.  Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism , 2016, Oncotarget.

[102]  Ali Shojaie,et al.  Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer , 2016, Nature Communications.

[103]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[104]  L. Butler,et al.  Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. , 2016, Endocrine-related cancer.

[105]  A. Harris,et al.  Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments , 2016, Cancer & metabolism.

[106]  J. Malm,et al.  Vitamin D, PTH, and calcium in relation to survival following prostate cancer , 2016, Cancer Causes & Control.

[107]  Yang Zhang,et al.  Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury , 2016, International journal of biological sciences.

[108]  A. Tjønneland,et al.  Selenium status and risk of prostate cancer in a Danish population , 2016, British Journal of Nutrition.

[109]  D. Wishart.  Emerging applications of metabolomics in drug discovery and precision medicine , 2016, Nature Reviews Drug Discovery.

[110]  R. Karnes,et al.  P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth , 2016, Oncotarget.

[111]  E. Giovannucci,et al.  Body size across the life course and prostate cancer in the Health Professionals Follow‐up Study , 2016, International journal of cancer.

[112]  E. White,et al.  Atg7 cooperates with Pten loss to drive prostate cancer tumor growth , 2016, Genes & development.

[113]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[114]  Lin Xu,et al.  PKM2 and cancer: The function of PKM2 beyond glycolysis , 2016, Oncology letters.

[115]  A. Raval,et al.  Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis , 2016, Prostate Cancer and Prostatic Diseases.

[116]  C. Collins,et al.  The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer , 2016, Clinical Cancer Research.

[117]  Oliver Fiehn,et al.  Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. , 2016, Analytical chemistry.

[118]  A. Briganti,et al.  Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. , 2015, European urology.

[119]  Takaya Nagasaki,et al.  Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth , 2015, Cancers.

[120]  Stacey A. Kenfield,et al.  Dairy intake after prostate cancer diagnosis in relation to disease‐specific and total mortality , 2015, International journal of cancer.

[121]  Guo-ping Xie,et al.  [Non-coding RNAs in castration-resistant prostate cancer]. , 2015, Zhonghua nan ke xue = National journal of andrology.

[122]  J. Kurhanewicz,et al.  Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor , 2015, The Prostate.

[123]  C. Coarfa,et al.  Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells , 2015, Oncotarget.

[124]  G. Andriole,et al.  Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study , 2015, Cancer Prevention Research.

[125]  H. Grönberg,et al.  Body mass index and mortality in men with prostate cancer , 2015, The Prostate.

[126]  M. V. Heiden,et al.  Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.

[127]  W. Willett,et al.  Intake of Meat Mutagens and Risk of Prostate Cancer in a Cohort of U.S. Health Professionals , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[128]  S. Clinton,et al.  A comparison of plasma and prostate lycopene in response to typical servings of tomato soup, sauce or juice in men before prostatectomy , 2015, British Journal of Nutrition.

[129]  D. Sabatini,et al.  An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.

[130]  E. Giannoni,et al.  Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread , 2015, Oncotarget.

[131]  D. Neal,et al.  Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer , 2015, Oncotarget.

[132]  E. Terreno,et al.  Probing treatment response of glutaminolytic prostate cancer cells to natural drugs with hyperpolarized [5‐13C]glutamine , 2015, Magnetic resonance in medicine.

[133]  E. Mittra,et al.  Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. , 2015 .

[134]  P. Zhou,et al.  MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. , 2015, American journal of cancer research.

[135]  D. Albanes,et al.  Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study , 2015, International journal of cancer.

[136]  Yibin Deng,et al.  Targeting hexokinase 2 in castration-resistant prostate cancer , 2015, Molecular & cellular oncology.

[137]  I. Thompson,et al.  Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial , 2015, Cancer Prevention Research.

[138]  Tomasz Burzykowski,et al.  Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  E. White,et al.  Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. , 2015, Cancer discovery.

[140]  J. Gustafsson,et al.  Targeting liver X receptors in cancer therapeutics , 2015, Nature Reviews Cancer.

[141]  M. V. Vander Heiden,et al.  Famine versus feast: understanding the metabolism of tumors in vivo. , 2015, Trends in biochemical sciences.

[142]  Dong Hoon Lee,et al.  Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. , 2015, Journal of the National Cancer Institute.

[143]  R. Singal,et al.  Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. , 2015, Clinical genitourinary cancer.

[144]  F. Baltazar,et al.  Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer , 2015, Journal of cellular and molecular medicine.

[145]  Ashish Gupta,et al.  Metabolomics-derived prostate cancer biomarkers: fact or fiction? , 2015, Journal of proteome research.

[146]  Yi-Fan Xu,et al.  Avoiding misannotation of in-source fragmentation products as cellular metabolites in liquid chromatography-mass spectrometry-based metabolomics. , 2015, Analytical chemistry.

[147]  guohua zhao,et al.  Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies , 2014, Oncology letters.

[148]  Stacey A. Kenfield,et al.  Selenium supplementation and prostate cancer mortality. , 2014, Journal of the National Cancer Institute.

[149]  F. Islami,et al.  A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. , 2014, European urology.

[150]  A. Zoubeidi,et al.  Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). , 2014, International journal of oncology.

[151]  P. Horák,et al.  HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells , 2014, Molecular Cancer Research.

[152]  Stacey A. Kenfield,et al.  Dietary Patterns after Prostate Cancer Diagnosis in Relation to Disease-Specific and Total Mortality , 2014, Cancer Prevention Research.

[153]  A. Harris,et al.  Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. , 2014, Cell reports.

[154]  Cesare R Sirtori,et al.  The pharmacology of statins. , 2014, Pharmacological research.

[155]  D. Albanes,et al.  1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. , 2014, Metabolomics : Official journal of the Metabolomic Society.

[156]  I. Mills,et al.  UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation , 2014, Oncogene.

[157]  Li-Ju Chang,et al.  Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. , 2014, Cell reports.

[158]  Leah Rider,et al.  Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[159]  J. Ioannidis,et al.  Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial , 2014, Diabetes Care.

[160]  Ian A Blair,et al.  Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. , 2014, Cell metabolism.

[161]  Stefan J. Barfeld,et al.  Androgen-regulated metabolism and biosynthesis in prostate cancer. , 2014, Endocrine-related cancer.

[162]  P. Goodman,et al.  Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[163]  S. Suissa,et al.  The Use of Metformin in Patients with Prostate Cancer and the Risk of Death , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[164]  P. Jiang,et al.  Regulation of the pentose phosphate pathway in cancer , 2014, Protein & Cell.

[165]  Judy Yan,et al.  Changes in PKM2 Associate with Prostate Cancer Progression , 2014, Cancer investigation.

[166]  E. Michelakis,et al.  A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation , 2014, Cell.

[167]  Q. Jiang.  Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. , 2014, Free radical biology & medicine.

[168]  U. Hofmann,et al.  A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer , 2014, Prostate Cancer and Prostatic Disease.

[169]  F. Baltazar,et al.  A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer , 2014, BMC Cancer.

[170]  A. Sjölander,et al.  Body mass index and weight change in men with prostate cancer: progression and mortality , 2014, Cancer Causes & Control.

[171]  Yan Shi,et al.  Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth , 2014, Oncogenesis.

[172]  A. Hsieh,et al.  PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance , 2014, Asian journal of andrology.

[173]  I. Thompson,et al.  Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[174]  M. Titus,et al.  Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer. , 2014, Current Metabolomics.

[175]  P. Paoli,et al.  Tumor microenvironment and metabolism in prostate cancer. , 2014, Seminars in oncology.

[176]  H. Kung,et al.  Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model , 2014, Oncogene.

[177]  Adriano Angelucci,et al.  Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression , 2014, BMC Cancer.

[178]  Ji-Xin Cheng,et al.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.

[179]  R. Wanders.  Metabolic functions of peroxisomes in health and disease. , 2014, Biochimie.

[180]  Ian M Thompson,et al.  Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. , 2014, Journal of the National Cancer Institute.

[181]  M. Loda,et al.  Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. , 2014, Journal of the National Cancer Institute.

[182]  A. Horiguchi,et al.  Increased fatty acid synthase expression in prostate biopsy cores predicts higher Gleason score in radical prostatectomy specimen , 2014, BMC Clinical Pathology.

[183]  H. Shimojo,et al.  Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients , 2013, Prostate Cancer and Prostatic Disease.

[184]  J. Winther,et al.  Non-invasive In-cell Determination of Free Cytosolic [NAD+]/[NADH] Ratios Using Hyperpolarized Glucose Show Large Variations in Metabolic Phenotypes* , 2013, The Journal of Biological Chemistry.

[185]  Jayantha B. Tennakoon,et al.  Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1α-Mediated Metabolic Switch , 2013, Oncogene.

[186]  M. Terris,et al.  Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database , 2013, Prostate Cancer and Prostatic Disease.

[187]  M. Gleave,et al.  Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. , 2013, Journal of the National Cancer Institute.

[188]  M. Loda,et al.  The fat side of prostate cancer. , 2013, Biochimica et biophysica acta.

[189]  J. Stanford,et al.  Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. , 2013, Cancer epidemiology.

[190]  John L Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, Journal of Clinical Investigation.

[191]  I. Mills,et al.  O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. , 2013, Cancer research.

[192]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[193]  E. Nintou,et al.  Cell Survival during Complete Nutrient Deprivation Depends on Lipid Droplet-fueled β-Oxidation of Fatty Acids* , 2013, The Journal of Biological Chemistry.

[194]  Jayoung Kim,et al.  MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells , 2013, PloS one.

[195]  P. Austin,et al.  Association between metformin use and risk of prostate cancer and its grade. , 2013, Journal of the National Cancer Institute.

[196]  R. Gillies,et al.  Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. , 2013, Cancer research.

[197]  Thomas M. Wasylenko,et al.  Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells , 2013, Nature Communications.

[198]  Kwok-Kin Wong,et al.  Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. , 2013, The Journal of clinical investigation.

[199]  S. Conti,et al.  Autophagy in Prostate Cancer and Androgen Suppression Therapy , 2013, International journal of molecular sciences.

[200]  J. Kurhanewicz,et al.  Hyperpolarized [1-13C]Dehydroascorbate MR Spectroscopy in a Murine Model of Prostate Cancer: Comparison with 18F-FDG PET , 2013, The Journal of Nuclear Medicine.

[201]  I. Mills,et al.  N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor , 2013, PloS one.

[202]  Gregory Stephanopoulos,et al.  The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.

[203]  V. Gudnason,et al.  Consumption of Fish Products across the Lifespan and Prostate Cancer Risk , 2013, PloS one.

[204]  M. Hediger,et al.  Zinc transporters in prostate cancer. , 2013, Molecular aspects of medicine.

[205]  E. Michelakis,et al.  Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology , 2013, Front. Oncol..

[206]  S. Ronen,et al.  Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells , 2013, NMR in biomedicine.

[207]  P. Woster,et al.  Polyamines and cancer: implications for chemotherapy and chemoprevention , 2013, Expert Reviews in Molecular Medicine.

[208]  C. Chuang,et al.  Anti-angiogenic effects of lycopene through immunomodualtion of cytokine secretion in human peripheral blood mononuclear cells. , 2013, The Journal of nutritional biochemistry.

[209]  R. Gillies,et al.  A new horizon of DNP technology: application to in-vivo 13C magnetic resonance spectroscopy and imaging , 2013, Biophysical Reviews.

[210]  M. Alves,et al.  Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. , 2012, The international journal of biochemistry & cell biology.

[211]  S. Yao,et al.  Liquid chromatography-mass spectrometric multiple reaction monitoring-based strategies for expanding targeted profiling towards quantitative metabolomics. , 2012, Current drug metabolism.

[212]  W. Shao,et al.  Expanding roles for SREBP in metabolism. , 2012, Cell metabolism.

[213]  D. English,et al.  Weight change and prostate cancer incidence and mortality , 2012, International journal of cancer.

[214]  F. Hamdy,et al.  Associations of circulating 25‐hydroxyvitamin D with prostate cancer diagnosis, stage and grade , 2012, International journal of cancer.

[215]  S. Mendrinos,et al.  The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer , 2012, Cancer biology & therapy.

[216]  J. Swinnen,et al.  ATP-citrate lyase: a key player in cancer metabolism. , 2012, Cancer research.

[217]  Liang Cheng,et al.  Dyslipidemia, statins and prostate cancer , 2012, Expert review of anticancer therapy.

[218]  A. Wolk,et al.  Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[219]  J. Malm,et al.  Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study , 2012, Cancer Causes & Control.

[220]  C. la Vecchia,et al.  Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. , 2012, The oncologist.

[221]  Chih-min Yang,et al.  Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. , 2012, Molecular nutrition & food research.

[222]  Dania Daye,et al.  Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. , 2012, Seminars in cell & developmental biology.

[223]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[224]  P. Kraft,et al.  Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. , 2012, Journal of the National Cancer Institute.

[225]  Y. Leung,et al.  Deprivation of arginine by recombinant human arginase in prostate cancer cells , 2012, Journal of Hematology & Oncology.

[226]  Stacey A. Kenfield,et al.  Milk and Dairy Consumption among Men with Prostate Cancer and Risk of Metastases and Prostate Cancer Death , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[227]  A. Cooper,et al.  Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings , 2011, British Journal of Nutrition.

[228]  R. Uzzo,et al.  Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. , 2011, Carcinogenesis.

[229]  L. Chung,et al.  Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.

[230]  J. Crowley,et al.  Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .

[231]  Kuniyasu Soda,et al.  The mechanisms by which polyamines accelerate tumor spread , 2011, Journal of experimental & clinical cancer research : CR.

[232]  J. Waxman,et al.  Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.

[233]  D. Moreira,et al.  Smoking and prostate cancer survival and recurrence. , 2011, Asian journal of andrology.

[234]  A. Wolk,et al.  Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study , 2011, British Journal of Cancer.

[235]  R. Reis,et al.  Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer , 2011, BMC Cancer.

[236]  Kai Yu,et al.  Serum 25-Hydroxy Vitamin D and Prostate Cancer Risk in a Large Nested Case–Control Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[237]  M. Loda,et al.  Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  P. Walsh,et al.  Cigarette smoking and prostate cancer recurrence after prostatectomy. , 2011, Journal of the National Cancer Institute.

[239]  A. Dudakovic,et al.  Bisphosphonates Induce Autophagy by Depleting Geranylgeranyl Diphosphate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[240]  I. Thompson,et al.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. , 2011, American journal of epidemiology.

[241]  J. Krycer,et al.  Cross-talk between the Androgen Receptor and the Liver X Receptor , 2011, The Journal of Biological Chemistry.

[242]  M. Stampfer,et al.  Prediagnostic Plasma Vitamin D Metabolites and Mortality among Patients with Prostate Cancer , 2011, PloS one.

[243]  Sanaz Memarzadeh,et al.  Differential transformation capacity of Src family kinases during the initiation of prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[244]  Chih-min Yang,et al.  Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. , 2011, Molecular nutrition & food research.

[245]  R. Komoroski,et al.  31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia , 2011, Magnetic resonance in medicine.

[246]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[247]  A. Means,et al.  CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. , 2011, Cancer research.

[248]  Ross J. Harris,et al.  Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis , 2011, Cancer Causes & Control.

[249]  S. Suissa,et al.  Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[250]  M. Terris,et al.  Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. , 2010, Urology.

[251]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[252]  Simon Hu,et al.  Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. , 2010, Cancer research.

[253]  Joseph S Koopmeiners,et al.  Vitamin D pathway gene variants and prostate cancer prognosis , 2010, The Prostate.

[254]  E. Giannoni,et al.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. , 2010, Cancer research.

[255]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[256]  David J Mener,et al.  Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature , 2010, IUBMB life.

[257]  M. T. Moser,et al.  Opposing Roles of Dnmt1 in Early- and Late-Stage Murine Prostate Cancer , 2010, Molecular and Cellular Biology.

[258]  G. Marceau,et al.  Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells , 2010, Oncogene.

[259]  J. Moulinoux,et al.  Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[260]  B. Kupelnick,et al.  Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. , 2010, American journal of public health.

[261]  John Kurhanewicz,et al.  Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. , 2010, Magnetic resonance imaging.

[262]  L. Chung,et al.  Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells* , 2010, The Journal of Biological Chemistry.

[263]  K. Fujita,et al.  Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. , 2009, The Journal of urology.

[264]  Robert V Farese,et al.  Lipid Droplets Finally Get a Little R-E-S-P-E-C-T , 2009, Cell.

[265]  Stacey A. Kenfield,et al.  Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[266]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[267]  David M. Evans,et al.  Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[268]  S. Koul,et al.  Oxidative stress in prostate cancer. , 2009, Cancer letters.

[269]  P. Tontonoz,et al.  LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor , 2009, Science.

[270]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[271]  N. Kitteringham,et al.  Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[272]  P. V. van Diest,et al.  Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. , 2009, Urology.

[273]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[274]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[275]  S. Tretli,et al.  Association between serum 25(OH)D and death from prostate cancer , 2009, British Journal of Cancer.

[276]  Frank Y. S. Chuang,et al.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. , 2009, Cancer research.

[277]  J. Manson,et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.

[278]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[279]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[280]  E. Riboli,et al.  Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. , 2008, The American journal of clinical nutrition.

[281]  Albert P. Chen,et al.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. , 2008, Cancer research.

[282]  J. Kurhanewicz,et al.  Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissues , 2008, Magnetic resonance in medicine.

[283]  M. Day,et al.  The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis , 2008, Oncogene.

[284]  H. Schünemann,et al.  Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study. , 2008, Urology.

[285]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[286]  Holly T. Sullivan,et al.  The Prostate 68 : 620 ^ 628 ( 2008 ) TheMetabolitesCitrate , Myo-Inositol , and Spermine Are PotentialAge-IndependentMarkers of Prostate Cancer inHumanExpressed Prostatic Secretions , 2008 .

[287]  M. Wangpaichitr,et al.  Arginine deprivation as a targeted therapy for cancer. , 2008, Current pharmaceutical design.

[288]  C. Poole,et al.  Systematic review of prostate cancer’s association with body size in childhood and young adulthood , 2008, Cancer Causes & Control.

[289]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[290]  Kevin Brindle,et al.  New approaches for imaging tumour responses to treatment , 2008, Nature Reviews Cancer.

[291]  Emily White,et al.  Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort , 2008, Cancer Causes & Control.

[292]  J. Swinnen,et al.  Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. , 2007, Cancer research.

[293]  R. Franklin,et al.  Zinc as an anti-tumor agent in prostate cancer and in other cancers. , 2007, Archives of biochemistry and biophysics.

[294]  M. Stampfer,et al.  A Prospective Study of Polyunsaturated Fatty Acid Levels in Blood and Prostate Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[295]  R. Franklin,et al.  hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands , 2007, Molecular Cancer.

[296]  A. Kristal,et al.  Anthropometrics and prostate cancer risk. , 2007, American journal of epidemiology.

[297]  L. Marton,et al.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases , 2007, Nature Reviews Drug Discovery.

[298]  L. Eapen,et al.  Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy , 2007, BJU international.

[299]  M. Inoue,et al.  Soy Product and Isoflavone Consumption in Relation to Prostate Cancer in Japanese Men , 2007, Cancer Epidemiology Biomarkers & Prevention.

[300]  D. Albanes,et al.  Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality , 2007, Cancer.

[301]  J. Dwyer,et al.  Biomolecular profiling of metastatic prostate cancer cells in bone marrow tissue using FTIR microspectroscopy: a pilot study , 2007, Analytical and bioanalytical chemistry.

[302]  Carmen Rodriguez,et al.  Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort , 2007, Cancer Epidemiology Biomarkers & Prevention.

[303]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[304]  A. Perry,et al.  The emerging roles of DNA methylation in the clinical management of prostate cancer. , 2006, Endocrine-related cancer.

[305]  R. Franklin,et al.  The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots , 2006, Molecular Cancer.

[306]  R. Hayes,et al.  Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. , 2006, Journal of the National Cancer Institute.

[307]  Ulrike Peters,et al.  A prospective study of meat and meat mutagens and prostate cancer risk. , 2005, Cancer research.

[308]  E. Giovannucci,et al.  Role of diet in prostate cancer development and progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[309]  O. Bagasra,et al.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer , 2005, Molecular Cancer.

[310]  E. John,et al.  Obesity before age 30 years and risk of advanced prostate cancer. , 2005, American Journal of Epidemiology.

[311]  R. Franklin,et al.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. , 2005, Mitochondrion.

[312]  T. Roskams,et al.  High‐level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB , 2005, The Journal of pathology.

[313]  W. Isaacs,et al.  Peroxisomal branched chain fatty acid β‐oxidation pathway is upregulated in prostate cancer , 2005, The Prostate.

[314]  K. Pienta,et al.  Bone turnover mediates preferential localization of prostate cancer in the skeleton. , 2005, Endocrinology.

[315]  Michael M Lieber,et al.  Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2005, Journal of the National Cancer Institute.

[316]  J. Swinnen,et al.  Androgens, lipogenesis and prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[317]  A. Roddam,et al.  A prospective study of diet and prostate cancer in Japanese men , 2004, Cancer Causes & Control.

[318]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[319]  R Engers,et al.  Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation , 2004, British Journal of Cancer.

[320]  F. Claessens,et al.  Identification of an Androgen Response Element in Intron 8 of the Sterol Regulatory Element-binding Protein Cleavage-activating Protein Gene Allowing Direct Regulation by the Androgen Receptor* , 2004, Journal of Biological Chemistry.

[321]  M. Resnick,et al.  Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. , 2004, The Journal of urology.

[322]  S. Tyldesley,et al.  The effect of smoking on outcome following external radiation for localized prostate cancer. , 2004, The Journal of urology.

[323]  M. Gleave,et al.  Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence , 2004, Cancer Research.

[324]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[325]  Lewis C Cantley,et al.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[326]  T. Thompson,et al.  Caveolin-1 Maintains Activated Akt in Prostate CancerCells through Scaffolding Domain Binding Site Interactions with andInhibition of Serine/Threonine Protein Phosphatases PP1 andPP2A , 2003, Molecular and Cellular Biology.

[327]  Yuet-Kin Leung,et al.  Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. , 2003, The American journal of pathology.

[328]  J. Minna,et al.  Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[329]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[330]  O. Bagasra,et al.  Prostate Cancer in African American Men Is Associated With Downregulation of Zinc Transporters , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[331]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[332]  N. Behrendt,et al.  Inuit are protected against prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[333]  J. Simons,et al.  Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[334]  B. Baird,et al.  A Lipid Raft Environment Enhances Lyn Kinase Activity by Protecting the Active Site Tyrosine from Dephosphorylation* , 2003, Journal of Biological Chemistry.

[335]  Y. Tokuda,et al.  Prostate cancer cell growth is modulated by adipocyte‐cancer cell interaction , 2003, BJU international.

[336]  B. Turnbull,et al.  Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial , 2003, BJU international.

[337]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[338]  D. English,et al.  Early growth, adult body size and prostate cancer risk , 2003, International journal of cancer.

[339]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[340]  R. Franklin,et al.  Direct effect of zinc on mitochondrial apoptogenesis in prostate cells , 2002, The Prostate.

[341]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[342]  E. Rimm,et al.  A prospective study of tomato products, lycopene, and prostate cancer risk. , 2002, Journal of the National Cancer Institute.

[343]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[344]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[345]  N. Reo.  NMR-BASED METABOLOMICS , 2002, Drug and chemical toxicology.

[346]  M. Stampfer,et al.  Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. , 2001, Journal of the National Cancer Institute.

[347]  K. M. Popov,et al.  Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. , 2001, The Biochemical journal.

[348]  Leo L. Cheng,et al.  Non‐destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T , 2001, FEBS letters.

[349]  M. Burns,et al.  Polyamine depletion therapy in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[350]  J. Benichou,et al.  Body size and prostate cancer: a population-based case-control study in China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[351]  A. Sabichi,et al.  Selenium effects on prostate cell growth. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[352]  Kai Simons,et al.  Lipid rafts and signal transduction , 2000, Nature Reviews Molecular Cell Biology.

[353]  A. Meikle,et al.  Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis , 2000, The Prostate.

[354]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[355]  J. Seidell,et al.  Body weight and weight change and their health implications for the elderly , 2000, European journal of clinical nutrition.

[356]  R. Goldbohm,et al.  Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. , 2000, American journal of epidemiology.

[357]  H Adlercreutz,et al.  Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice , 2000, The Prostate.

[358]  E. Rimm,et al.  Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[359]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[360]  S. Sasaki,et al.  Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. , 1999, Preventive medicine.

[361]  R. Franklin,et al.  Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer , 1998, The Prostate.

[362]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[363]  S. Ripatti,et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. , 1998, Journal of the National Cancer Institute.

[364]  L. Clark,et al.  Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. , 1998, Cancer letters.

[365]  J. Swinnen,et al.  Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[366]  R. Franklin,et al.  Zinc Inhibition of Mitochondrial Aconitase and Its Importance in Citrate Metabolism of Prostate Epithelial Cells* , 1997, The Journal of Biological Chemistry.

[367]  E. Rimm,et al.  Height, body weight, and risk of prostate cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[368]  W. Stahl,et al.  Lycopene is more bioavailable from tomato paste than from fresh tomatoes. , 1997, The American journal of clinical nutrition.

[369]  W. Mazur,et al.  Phyto-oestrogens and Western diseases. , 1997, Annals of medicine.

[370]  E. Kyle,et al.  Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. , 1997, Molecular pharmacology.

[371]  H. Adami,et al.  Lifestyle factors and prostate cancer risk: a case-control study in Sweden. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[372]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[373]  S. Meydani,et al.  Vitamin E and aging immune response. , 1995, Clinics in geriatric medicine.

[374]  J. Néve,et al.  Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. , 1995, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[375]  J. Hisnanick,et al.  Cancer incidence among American Indians and Alaska Natives, 1980 through 1987. , 1993, American journal of public health.

[376]  A. Admon,et al.  SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene , 1993, Cell.

[377]  M. Gail,et al.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. , 1993, Journal of the National Cancer Institute.

[378]  M. Webber,et al.  Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. , 1986, The Journal of urology.

[379]  M. Ookhtens,et al.  Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. , 1984, The American journal of physiology.

[380]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[381]  Tricia T. Nguyen,et al.  PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells. , 2018, Cancer discovery.

[382]  Hengjun Xiao,et al.  Increased expression of glycolytic enzymes in prostate cancer tissues and association with Gleason scores. , 2017, International journal of clinical and experimental pathology.

[383]  Robert Schmieder,et al.  Organ-Specific Cancer Metabolism and Its Potential for Therapy. , 2016, Handbook of experimental pharmacology.

[384]  H. Hricak,et al.  Molecular Imaging of Prostate Cancer. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.

[385]  F. Speizer,et al.  Smoking and Mortality - Beyond Established Causes. , 2016, The New England journal of medicine.

[386]  M. Alves,et al.  Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes , 2015, Journal of Cancer Research and Clinical Oncology.

[387]  E. Giovannucci,et al.  Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. , 2015, The American journal of clinical nutrition.

[388]  J. Debnath,et al.  Autophagy and cancer metabolism. , 2014, Methods in enzymology.

[389]  S. Gandini,et al.  Vitamin D receptor polymorphisms and cancer. , 2014, Advances in experimental medicine and biology.

[390]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[391]  M. V. Vander Heiden.  Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[392]  J. Rasko,et al.  Molecular and Cellular Pathobiology Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression , 2011 .

[393]  M. Roizen.  Fish consumption and prostate cancer risk: a review and meta-analysis , 2011 .

[394]  R. Franklin,et al.  Zinc is decreased in prostate cancer: an established relationship of prostate cancer! , 2010, JBIC Journal of Biological Inorganic Chemistry.

[395]  S. Rohrmann,et al.  Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort , 2010, Cancer Causes & Control.

[396]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[397]  K. Biermann,et al.  CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. , 2008, Urology.

[398]  M. Freeman,et al.  Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in , 2007 .

[399]  Stephanie Daignault,et al.  Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. , 2006, Cancer research.

[400]  I. G. Fantus,et al.  The Hexosamine Biosynthesis Pathway , 2006 .

[401]  J. Barrio,et al.  Radiation Dose Estimates in Humans for 11 CAcetate CAcetate CAcetate Whole-Body PET , 2004 .

[402]  Y. Chen,et al.  Human prostate cancer cells lack feedback regulation of low‐density lipoprotein receptor and its regulator, SREBP2 , 2001, International journal of cancer.

[403]  D. Brenner,et al.  Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism. , 2000, Gastroenterology.

[404]  C D Gardner,et al.  Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. , 1998, The Journal of clinical endocrinology and metabolism.

[405]  Sheila M. Williams,et al.  Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. , 1998, The American journal of clinical nutrition.

[406]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[407]  B W Turnbull,et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. , 1996, JAMA.

[408]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[409]  S. Barnes,et al.  Soy intake and cancer risk: a review of the in vitro and in vivo data. , 1994, Nutrition and cancer.

[410]  R. Pasquali,et al.  Effect of obesity and body fat distribution on sex hormones and insulin in men. , 1991, Metabolism: clinical and experimental.

[411]  R. Franklin,et al.  Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate. , 1981, Enzyme.